LCE2B

Across TCGA pan-cancer cohorts, LCE2B RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated LCE2B data layer compared with 3 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LCE2B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCE2B expression acts as an unfavorable survival marker, although some lineages such as ESCA and HNSC show a favorable association.

BLCA, MESO, and UCEC are the cancer types where LCE2B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.212	0.541	<.001	108	view →
MESO	OS	Tertile	II,III,IV	0.183	0.566	.004	81	view →
UCEC	OS	Tertile	All	0.788	0.929	<.001	72	view →
SKCM	OS	Tertile	All	0.160	0.353	.001	57	view →
STAD	DFS	Tertile	All	0.302	0.564	.009	36	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
LAML	DFS	Tertile	All	0.028	0.572	<.001	36	view →
PRAD	OS	Tertile	All	0.693	0.990	<.001	18	view →
ESCA	OS	Tertile	II,III,IV	0.819	0.650	.019	17	view →
SARC	OS	Tertile	All	0.123	0.495	.007	15	view →
THCA	OS	Tertile	II,III,IV	0.940	0.983	.010	12	view →
LIHC	OS	Tertile	II,III,IV	0.255	0.768	.018	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

LCE2B–BLCA (DFS)

Open the BLCA breakdown →